Therapeutic Potential of miRNAs for Type 2 Diabetes Mellitus: An Overview.

IF 3.2 Q2 GENETICS & HEREDITY

Epigenetics Insights Pub Date : 2022-10-15 eCollection Date: 2022-01-01 DOI:10.1177/25168657221130041

Pads Palihaderu, Bilm Mendis, Jmkjk Premarathne, Wkrr Dias, Swee Keong Yeap, Wan Yong Ho, A S Dissanayake, I H Rajapakse, P Karunanayake, U Senarath, D A Satharasinghe

{"title":"Therapeutic Potential of miRNAs for Type 2 Diabetes Mellitus: An Overview.","authors":"Pads Palihaderu, Bilm Mendis, Jmkjk Premarathne, Wkrr Dias, Swee Keong Yeap, Wan Yong Ho, A S Dissanayake, I H Rajapakse, P Karunanayake, U Senarath, D A Satharasinghe","doi":"10.1177/25168657221130041","DOIUrl":null,"url":null,"abstract":"<p><p>MicroRNA(miRNA)s have been identified as an emerging class for therapeutic interventions mainly due to their extracellularly stable presence in humans and animals and their potential for horizontal transmission and action. However, treating Type 2 diabetes mellitus using this technology has yet been in a nascent state. MiRNAs play a significant role in the pathogenesis of Type 2 diabetes mellitus establishing the potential for utilizing miRNA-based therapeutic interventions to treat the disease. Recently, the administration of miRNA mimics or antimiRs in-vivo has resulted in positive modulation of glucose and lipid metabolism. Further, several cell culture-based interventions have suggested beta cell regeneration potential in miRNAs. Nevertheless, few such miRNA-based therapeutic approaches have reached the clinical phase. Therefore, future research contributions would identify the possibility of miRNA therapeutics for tackling T2DM. This article briefly reported recent developments on miRNA-based therapeutics for treating Type 2 Diabetes mellitus, associated implications, gaps, and recommendations for future studies.</p>","PeriodicalId":41996,"journal":{"name":"Epigenetics Insights","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/2f/10.1177_25168657221130041.PMC9575458.pdf","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epigenetics Insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25168657221130041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 6

Abstract

MicroRNA(miRNA)s have been identified as an emerging class for therapeutic interventions mainly due to their extracellularly stable presence in humans and animals and their potential for horizontal transmission and action. However, treating Type 2 diabetes mellitus using this technology has yet been in a nascent state. MiRNAs play a significant role in the pathogenesis of Type 2 diabetes mellitus establishing the potential for utilizing miRNA-based therapeutic interventions to treat the disease. Recently, the administration of miRNA mimics or antimiRs in-vivo has resulted in positive modulation of glucose and lipid metabolism. Further, several cell culture-based interventions have suggested beta cell regeneration potential in miRNAs. Nevertheless, few such miRNA-based therapeutic approaches have reached the clinical phase. Therefore, future research contributions would identify the possibility of miRNA therapeutics for tackling T2DM. This article briefly reported recent developments on miRNA-based therapeutics for treating Type 2 Diabetes mellitus, associated implications, gaps, and recommendations for future studies.

Abstract Image

查看原文本刊更多论文

mirna治疗2型糖尿病的潜力:综述

MicroRNA(miRNA)已被确定为一类新兴的治疗干预措施，主要是因为它们在人类和动物体内的细胞外稳定存在，以及它们水平传播和作用的潜力。然而，使用这种技术治疗2型糖尿病还处于初级阶段。mirna在2型糖尿病的发病机制中发挥着重要作用，为利用基于mirna的治疗干预手段治疗该疾病奠定了基础。最近，体内给药miRNA模拟物或抗miRNA导致糖脂代谢的正向调节。此外，一些基于细胞培养的干预措施表明mirna具有β细胞再生潜力。然而，这种基于mirna的治疗方法很少进入临床阶段。因此，未来的研究将确定miRNA治疗T2DM的可能性。本文简要报道了基于mirna治疗2型糖尿病的最新进展、相关意义、差距和对未来研究的建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊